Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• 5'-Methylthioadenosine (MTA) is a naturally occurring nucleoside.
• MTA is degraded by MTA phosphorylase (MTAase) into adenine and methylthioribose-1-phosphate in normal mammalian cells.
• These degradation products are recycled into essential cellular pathways, supporting normal cell function.

Purpose of the Study:

• To investigate the prevalence of MTAase deficiency in various human neoplasms.
• To determine if MTAase deficiency is a common characteristic of malignant cells.
• To explore the potential therapeutic implications of MTAase deficiency in cancer treatment.

Main Methods:

• Assay of MTAase activity in malignant cells from patients with acute nonlymphocytic leukemia and solid tumors.
• Comparison of MTAase activity in malignant cells versus normal cells (erythrocytes, neutrophils, monocytes).
• Evaluation of the impact of sample preservation and processing methods on MTAase activity.

Main Results:

• MTAase activity was undetectable in malignant cells from one acute nonlymphocytic leukemia patient and three solid tumor patients (melanoma, lung squamous cell carcinoma, rectal adenocarcinoma).
• Normal cells (erythrocytes, neutrophils, monocytes) from healthy subjects and cancer patients consistently showed MTAase activity.
• Sample handling procedures did not compromise MTAase activity measurements.

Conclusions:

• MTAase deficiency is present in a subset of human malignancies, including acute nonlymphocytic leukemia and various solid tumors.
• This metabolic difference distinguishes malignant cells from normal cells.
• The exploitable metabolic difference in MTAase activity presents a potential therapeutic target for cancer treatment.